Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 17, 2016, Pages

  Klocke, Katrin ^a   Sakaguchi, Shimon ^b   Holmdahl, Rikard ^a   Wing, Kajsa ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Autoimmunity; CTLA 4; Foxp3; Regulatory T cells; Tolerance

Indexed keywords

AUTOANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADULTHOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTHRITIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL AUTOIMMUNE DISEASE; GASTRITIS; GENE DELETION; GENETIC ASSOCIATION STUDY; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGICAL TOLERANCE; INSULITIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MYOCARDITIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SALIVARY GLAND FUNCTION; SIALOADENITIS; T LYMPHOCYTE ACTIVATION; THYMOCYTE; ANIMAL; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; AUTOIMMUNITY; C57BL MOUSE; DEFICIENCY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CTLA-4 ANTIGEN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY;

EID: 84964778827     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1603892113     Document Type: Article

References (62)

1. Takahashi T, et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-Associated antigen J Exp Med 192(2):303-310.
2. Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229(1):12-26.
3. Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445-450.
4. Kuehn HS, et al. (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623-1627.
5. Schubert D, et al. (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410-1416.
6. Kouki T, et al. (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165(11):6606-6611.
7. Barreto M, et al. (2004) Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 12(8):620-626.
8. Marron MP, et al. (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 6(8): 1275-1282.
9. Tang M-J, Zhou Z-B (2013) Association of the CTLA-4 +49A/G polymorphism with rheumatoid arthritis in Chinese Han population. Mol Biol Rep 40(3):2627-2631.
10. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
11. Horvat TZ, et al. (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193-3198.
12. Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37(5):499-507.
13. Waterhouse P, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985-988.
14. Tivol EA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541-547.
15. Wing K, et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271-275.
16. Read S, et al. (2006) Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177(7):4376-4383.
17. Verhagen J, et al. (2009) Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proc Natl Acad Sci USA 106(9): 3306-3311.
18. Paterson AM, et al. (2015) Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med 212(10):1603-1621.
19. Schmidt EM, et al. (2009) Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 182(1):274-282.
20. Wing K, Yamaguchi T, Sakaguchi S (2011) Cell-Autonomous and-non-Autonomous roles of CTLA-4 in immune regulation. Trends Immunol 32(9):428-433.
21. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183(6):2533-2540.
22. Lee KM, et al. (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282(5397):2263-2266.
23. Linsley PS, et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174(3):561-569.
24. van derMerwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185(3):393-403.
25. Bachmann MF, Köhler G, Ecabert B, Mak TW, Kopf M (1999) Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 163(3):1128-1131.
26. Tivol EA, Gorski J (2002) Re-establishing peripheral tolerance in the absence of CTLA-4: Complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 169(4):1852-1858.
27. Takahashi S, et al. (2005) In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur J Immunol 35(2):399-407.
28. Corse E, Allison JP (2012) Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189(3):1123-1127.
29. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29):10113-10118.
30. Qureshi OS, et al. (2011) Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600-603.
31. Grohmann U, et al. (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3(11):1097-1101.
32. Chambers CA, Cado D, Truong T, Allison JP (1997) Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 94(17):9296-9301.
33. Wagner DH, Jr., et al. (1996) Rescue of thymocytes from glucocorticoid-induced cell death mediated by CD28/CTLA-4 costimulatory interactions with B7-1/B7-2. J Exp Med 184(5):1631-1638.
34. Cilio CM, Daws MR, Malashicheva A, Sentman CL, Holmberg D (1998) Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J Exp Med 188(7): 1239-1246.
35. Buhlmann JE, Elkin SK, Sharpe AH (2003) A role for the B7-1/B7-2:CD28/CTLA-4 pathway during negative selection. J Immunol 170(11):5421-5428.
36. Verhagen J, et al. (2013) CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc Natl Acad Sci USA 110(3):E221-E230.
37. Elshazli R, Settin A, Salama A (2015) Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) +49 AG gene polymorphism in Egyptian cases with rheumatoid arthritis. Gene 558(1):103-107.
38. Torres-Carrillo N, et al. (2013) The-319C/+49G/CT60G haplotype of CTLA-4 gene confers susceptibility to rheumatoid arthritis in Mexican population. Cell Biochem Biophys 67(3):1217-1228.
39. Li X, et al. (2012) Polymorphisms in the CTLA-4 gene and rheumatoid arthritis susceptibility: A meta-Analysis. J Clin Immunol 32(3):530-539.
40. von Kempis J, et al. (2012) Use of abatacept in rheumatoid arthritis. Swiss Med Wkly 142:w13581.
41. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ (1995) Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 96(2): 987-993.
42. Codarri L, et al. (2011) ROR?t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560-567.
43. Lyons JA, San M, Happ MP, Cross AH (1999) B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29(11):3432-3439.
44. Svensson L, et al. (2002) A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur J Immunol 32(7):1939-1946.
45. Walker LSK, Sansom DM (2015) Confusing signals: Recent progress in CTLA-4 biology. Trends Immunol 36(2):63-70.
46. Walker LSK (2013) Treg and CTLA-4: Two intertwining pathways to immune tolerance. J Autoimmun 45:49-57.
47. Ise W, et al. (2010) CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 11(2):129-135.
48. Yamaguchi T, et al. (2013) Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci USA 110(23):E2116-E2125.
49. Hood JD, Zarnitsyna VI, Zhu C, Evavold BD (2015) Regulatory and T effector cells have overlapping low to high ranges in TCR affinities for self during demyelinating disease. J Immunol 195(9):4162-4170.
50. Gebe JA, et al. (2003) Low-Avidity recognition by CD4+ T cells directed to self-Antigens. Eur J Immunol 33(5):1409-1417.
51. Sabatino JJ, Jr., Huang J, Zhu C, Evavold BD (2011) High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med 208(1):81-90.
52. Yang S, Fujikado N, Kolodin D, Benoist C, Mathis D (2015) Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance. Science 348(6234):589-594.
53. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP (1997) Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 73(1-2):57-62.
54. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK (1996) CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 157(4):1333-1336.
55. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184(2):783-788.
56. Svensson L, Jirholt J, Holmdahl R, Jansson L (1998) B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 111(3):521-526.
57. Sage PT, Paterson AM, Lovitch SB, Sharpe AH (2014) The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41(6):1026-1039.
58. Wing JB, Ise W, Kurosaki T, Sakaguchi S (2014) Regulatory T cells control antigenspecific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41(6):1013-1025.
59. Wang CJ, et al. (2015) CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci USA 112(2):524-529.
60. Winter S, et al. (2011) Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice. Am J Pathol 179(2):754-765.
61. Miller GL (1959) Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal Chem 31(3):426-428.
62. Smith BD, Martin GR, Miller EJ, Dorfman A, Swarm R (1975) Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys 166(1): 181-186.